Targeting the Src N-terminal regulatory element in cancer
Data de publicació
2023ISSN
1949-2553
Resum
The signaling pathways displayed by cancer cells are often composed by the same components than the physiological ones, yet the overall result is a pathological deregulation. The non-receptor protein tyrosine kinase Src is a good example. Src is the first described proto-oncogene and a demonstrated player in cancer progression, as it affects proliferation, invasion, survival, cancer stemness, and drug resistance. Src activation is linked to poor prognosis in many cancer types, yet mutations in this protein are rarely observed. In addition, being a demonstrated cancer target, unspecific inhibition of the kinase activity has proven inefficient in clinics since the inhibition of Src in non-cancerous cells results in unacceptable toxicity. Thus, there is a need for new target regions in Src that could inhibit Src activity only in certain cell types, e.g., cancer cells, while maintaining the normal physiological activity in healthy cells. The Src N-terminal regulatory element (SNRE) includes the poorly studied intrinsically disordered region with unique sequences for each of the members of the Src family. In this perspective, we discuss the non-canonical regulatory mechanisms involving the SNRE and their potential use as oncotargets.
Tipus de document
Article
Versió del document
Versió publicada
Llengua
Anglès
Matèries (CDU)
61 - Medicina
616 - Patologia. Medicina clínica. Oncologia
Paraules clau
Pàgines
11
Publicat per
Impact Journals
Col·lecció
14
Publicat a
Oncotarget
Citació
Mezquita, Betlem; Reyes Farias, Marjorie; Pons, Miquel. Targeting the Src N-terminal regulatory element in cancer. Oncotarget, 2023, 14, 503-513. Disponible en: <https://www.oncotarget.com/article/28434/text/>. Fecha de acceso: 7 jun. 2023. DOI: 10.18632/oncotarget.28434
Número de l'acord de la subvenció
info:eu-repo/grantAgreement/ES/MICINN/PID2019-104914RB-I00
info:eu-repo/grantAgreement/ES/MICINN/PDC2021-121629-I00
Nota
We acknowledge extensive discussions with present and former members of the Pons’ group and the sustained collaboration with Serge Roche’s group in Montpellier. The Pons’ lab is financed by
the Spanish Ministry of Science and Innovation (PID2019-104914RB-I00; PDC2021-121629-I00). The collaboration with the Roche group is financed by the French Agence Nationale de la Recherche (FUZZY-SRC ANR-21-CE13-0011).
Enllaç al document relacionat
Aquest element apareix en la col·lecció o col·leccions següent(s)
- Ciències de la Salut [952]
Drets
© 2023 Mezquita et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Excepte que s'indiqui una altra cosa, la llicència de l'ítem es descriu com https://creativecommons.org/licenses/by/3.0/